nVerses Capital LLC Makes New $80,000 Investment in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

nVerses Capital LLC bought a new position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,200 shares of the company’s stock, valued at approximately $80,000.

Other hedge funds have also added to or reduced their stakes in the company. Essex Investment Management Co. LLC lifted its position in shares of Kiniksa Pharmaceuticals by 0.4% in the 3rd quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after purchasing an additional 717 shares during the period. CWM LLC lifted its position in shares of Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. Algert Global LLC lifted its position in shares of Kiniksa Pharmaceuticals by 78.1% in the 2nd quarter. Algert Global LLC now owns 18,603 shares of the company’s stock worth $347,000 after purchasing an additional 8,156 shares during the period. Lynx1 Capital Management LP purchased a new stake in shares of Kiniksa Pharmaceuticals in the 2nd quarter worth approximately $177,000. Finally, Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals by 159.8% in the 2nd quarter. Millennium Management LLC now owns 621,948 shares of the company’s stock worth $11,612,000 after purchasing an additional 382,539 shares during the period. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KNSA. Jefferies Financial Group began coverage on shares of Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They issued a “buy” rating and a $40.00 price target for the company. Wedbush upped their price target on shares of Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $33.60.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 24,248 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $24.79, for a total transaction of $601,107.92. Following the transaction, the chief financial officer now owns 19,253 shares in the company, valued at approximately $477,281.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $26.87, for a total transaction of $456,790.00. Following the transaction, the chief operating officer now owns 109,975 shares in the company, valued at approximately $2,955,028.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Mark Ragosa sold 24,248 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $24.79, for a total transaction of $601,107.92. Following the transaction, the chief financial officer now owns 19,253 shares in the company, valued at $477,281.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 295,064 shares of company stock worth $7,622,044. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Stock Down 1.8 %

NASDAQ:KNSA opened at $26.26 on Monday. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $14.12 and a 52 week high of $27.92. The firm has a 50 day moving average of $25.58 and a 200 day moving average of $21.96. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 238.73 and a beta of 0.33.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its earnings results on Tuesday, July 23rd. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative net margin of 3.10% and a negative return on equity of 7.79%. The company had revenue of $108.30 million during the quarter, compared to analysts’ expectations of $90.60 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. Kiniksa Pharmaceuticals’s revenue for the quarter was up 51.5% compared to the same quarter last year. As a group, analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.29 EPS for the current year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.